



US009241622B2

(12) **United States Patent**  
**Ornberg et al.**

(10) **Patent No.:** **US 9,241,622 B2**  
(45) **Date of Patent:** **Jan. 26, 2016**

(54) **METHOD FOR OCULAR SURFACE IMAGING**

USPC ..... 600/407, 431, 473, 476–478  
See application file for complete search history.

(75) Inventors: **Richard L. Ornberg**, Burleson, TX  
(US); **Gary W. Williams**, Burleson, TX  
(US)

(56) **References Cited**

(73) Assignee: **Alcon Research, Ltd.**, Fort Worth, TX  
(US)

U.S. PATENT DOCUMENTS

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 15 days.

5,852,498 A	12/1998	Youvan et al.
5,986,271 A	11/1999	Lazarev et al.
5,988,271 A	11/1999	Oneal et al.
6,006,756 A	12/1999	Shaddock
6,044,196 A	3/2000	Winston et al.

(Continued)

(21) Appl. No.: **13/026,659**

FOREIGN PATENT DOCUMENTS

(22) Filed: **Feb. 14, 2011**

CN	1833257 A	9/2006
EP	2172150	7/2010

(65) **Prior Publication Data**

(Continued)

US 2011/0164218 A1 Jul. 7, 2011

OTHER PUBLICATIONS

**Related U.S. Application Data**

(63) Continuation-in-part of application No. 12/704,083,  
filed on Feb. 11, 2010.

Begley et al.; “Effect of lens care systems on corneal fluorescein  
staining and subjective comfort in hydrogel lens wearers”; Clinical  
Article: ICLC; vol. 21; pp. 7-13 (Jan./Feb. 1994).

(Continued)

(60) Provisional application No. 61/151,880, filed on Feb.  
12, 2009.

*Primary Examiner* — Mark Remaly

(74) *Attorney, Agent, or Firm* — Haynes and Boone, LLP

(51) **Int. Cl.**

**A61B 3/10** (2006.01)

**G06T 7/00** (2006.01)

(57) **ABSTRACT**

(52) **U.S. Cl.**


CPC ..... **A61B 3/10** (2013.01); **G06T 7/0012**  
(2013.01); **G06T 2207/10012** (2013.01); **G06T**  
**2207/10056** (2013.01); **G06T 2207/10064**  
(2013.01); **G06T 2207/20056** (2013.01); **G06T**  
**2207/30041** (2013.01)

The invention provides methods for detecting ocular surface  
defects. The methods of the invention can be used to detect  
ocular surface diseases, such as dry eye, uveitis, conjunctivi-  
tis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis  
(VKC), atopic keratoconjunctivitis (AKC), autoimmune dis-  
orders of the ocular surface, meibomianitis, conjunctival  
hyperemia, eyelid hyperemia, ocular rosacea, ocular inflam-  
mation, or eye lid swelling.

(58) **Field of Classification Search**

CPC ..... A61B 5/0059; A61B 5/0077; A61B 3/12;  
A61B 5/6821; A61B 5/7257; A61B 1/00186

**14 Claims, 7 Drawing Sheets**



(56)

**References Cited**

## U.S. PATENT DOCUMENTS

6,049,367	A	4/2000	Sharp et al.	
6,252,979	B1	6/2001	Lee et al.	
6,299,305	B1	10/2001	Miwa	
7,860,286	B2	12/2010	Wang et al.	
7,889,948	B2	2/2011	Steedly et al.	
8,292,878	B2	10/2012	Arnoldussen et al.	
2002/0151774	A1	10/2002	Soller et al.	
2003/0163049	A1	8/2003	Balas	
2005/0105788	A1	5/2005	Turek et al.	
2005/0134796	A1	6/2005	Zelvin et al.	
2006/0077581	A1	4/2006	Schwiegerling et al.	
2006/0099714	A1	5/2006	Mata et al.	
2006/0142662	A1 *	6/2006	Van Beek	600/476
2006/0274269	A1 *	12/2006	Koest	351/246
2007/0046778	A1	3/2007	Ishihara et al.	
2008/0077581	A1	3/2008	Drayer et al.	
2008/0086048	A1	4/2008	Dupps, Jr. et al.	
2008/0090198	A1	4/2008	Liang et al.	
2008/0239070	A1	10/2008	Westwick et al.	
2009/0153798	A1	6/2009	Dick et al.	
2010/0004537	A1	1/2010	Eilers et al.	
2010/0004538	A1	1/2010	Eilers et al.	
2010/0079580	A1	4/2010	Waring, IV	
2010/0128960	A1	5/2010	Yumikake	
2010/0204584	A1	8/2010	Ornberg	
2011/0200242	A1	8/2011	Takama et al.	
2011/0202044	A1	8/2011	Goldshleger et al.	
2011/0262891	A1	10/2011	Ozaki et al.	
2011/0274322	A1	11/2011	Kern	

## FOREIGN PATENT DOCUMENTS

JP	07-039519	10/1995
JP	2000-237135	5/2000
JP	2000-296109	10/2000
JP	2007-090044	12/2007
JP	2008-264137	11/2008

JP	2009-502220	1/2009
WO	WO 2010/039206 A1	4/2010
WO	2010093772 A1	8/2010
WO	WO 2011/139827	10/2011

## OTHER PUBLICATIONS

Bron et al.; "Grading of corneal and conjunctival staining in the context of other dry eye tests"; Cornea; Clinical Sciences; vol. 22; No. 7; pp. 640-650 (Oct. 2003).

Dean et al.; "Clinical Technique; Documentation of corneal epithelial defects with fluorescein-enhanced digital fundus camera photography"; Clinical and Experimental Ophthalmology; vol. 36; pp. 113-118 (2008).

Lemp; "Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes"; CLAO; vol. 21, No. 4; pp. 221-232 (Oct. 1995).

Novitskaya et al.; "A novel method to study fluorescein staining of the ocular surface using the fluorescein angiogram setting of the fundus camera"; Contact Lens & Anterior Eye; vol. 30; pp. 258-259 (2007). International Search Report corresponding to PCT Application Serial No. PCT/US2010/023865 dated Apr. 7, 2010.

Written Opinion corresponding to PCT Application Serial No. PCT/US2010/023865 dated Apr. 7, 2010.

Saari, K. Matti; "Immunology of the lacrimal gland, tear film and ocular surface;" Book Review, Graefe's Archive of Clinical Experimental Ophthalmology; vol. 245; p. 471 (2007).

Stachs, Oliver, et al., "In vivo three-dimensional confocal laser scanning microscopy of the epithelial nerve structure in the human cornea," Laboratory Investigation; Graefe's Archive for Clinical Experimental Ophthalmology; vol. 245, No. 4, Mar. 20, 2007; pp. 569-575, XP55004942, ISSN: 0721-832X, DOI: 10.1007/s00417-006-0387-2, figures 1-5.

European Patent Office, International Search Report and Written Opinion dated Aug. 26, 2011, Application No. PCT/US2011/034304, 15 pages.

\* cited by examiner




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B






FIG. 3C



**FIG. 4A**



**FIG. 4B**




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D






FIG. 7A




FIG. 7B

1

**METHOD FOR OCULAR SURFACE IMAGING****CROSS-REFERENCE TO RELATED APPLICATION**

This application is a continuation-in-part application of Ser. No. 12/704,083, filed Feb. 11, 2010, which claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application No. 61/151,880 filed Feb. 12, 2009, the entire contents of which are incorporated herein by reference.

**FIELD OF THE INVENTION**

The invention relates to apparatuses and methods for detecting ocular surface defects or the absence thereof. An apparatus and method of the invention can be used, for example, to detect ocular surface diseases.

**BACKGROUND OF THE INVENTION**

The diagnosis and prognosis of ocular surface diseases, such as keratoconjunctivitis sicca (dry eye), involves several tests. One of the tests includes staining the ocular surface with a dye, followed by visual examination for stained surface defects. Lesions in the epithelial cell layers of the cornea adsorb stain and allow for the penetration of stain into interstitial spaces. The resultant bright speckled appearance of the otherwise black cornea is a hallmark pathology of cornea disease. Visual examination has been used since the early 1900s as a diagnostic for surface eye disease. However, the variability and reliability of these assessments has been poor when performed by individual physicians. Hence there is an urgent need for a consistent measure of surface staining that is free of human bias and error. Heretofore, quantitative image analysis of ocular surface images has proven difficult for at least three reasons.

The first reason relates to Purkinje images of the illumination source in the images of the cornea and conjunctiva. The Purkinje image invariably interferes with image analysis and feature detection. Since it is not constant from one image to the next, such specular images are impossible to control for and must be removed prior to image analysis. Spectral methods are routinely used in fluorescence microscopy and whole body imaging to block undesired reflected light. Novitskaya et al. and Dean et al. described the use of a retinal camera having filtering properties for ocular surface stain imaging (Novitskaya et al., 2007, *Contact Lens & Anterior Eye* 30:258-259; Dean et al., 2008, *Clinical and Experimental Ophthalmology* 36:113-118). Novitskaya et al. and Dean et al. used digital fundus camera equipped with two filters, a blue exciter filter and a green bandpass filter, to detect fluorescence emitted from a fluorescein stained cornea. The fundus camera is designed to image fluorescein injected in to the vasculature as a means to assess retinal blood flow. The spectral properties of these filters were not described.

A second difficulty in accurately detecting and measuring corneal stain relates to the methods used to capture corneal images. Any object in an image that is to be measured has to be in sharp focus in order to visually or mathematically delineate the boundaries of the object. Stained objects on the corneal surface reside on a highly curved surface and require the use of methods that increase the depth of focus or depth of field in the image. The average height of the cornea from the limbal edge to the apex, also called the sag height is 2.8 millimeters for the human eye. The standard of care diagnostic system for viewing and imaging the cornea uses a biomicroscope on a slit lamp that has a depth of field of 0.7-0.8 mm

2

on average. Hence any given stained corneal image from such a system can not possibly have all stained objects in sharp focus for subsequent analysis. Other imaging systems such as the retinal camera described by Novitskaya et al. and Dean et al. have a similar narrow depth of field for adequate image capture of the stained cornea.

A third difficulty in accurately detecting and measuring corneal stain relates to the methods used to separate surface stained objects from surrounding image elements for subsequent measurement. Images of stained ocular surfaces from patients with dry eye or other ocular surface diseases generally have bright punctate stained objects of interest amidst a background fluorescence that is an unwanted signal and is not to be included in the measurement.

Consequently, there is a need in the art to eliminate unwanted specular images in corneal staining and to capture full field in focus images of the corneal surface while enhancing a light signal that represents ocular surface defects for accurate diagnosis and monitoring of corneal surface diseases.

**SUMMARY OF THE INVENTION**

The invention provides methods of detecting ocular surface diseases, the methods comprising: (a) illuminating the ocular surface of an eye of a patient with a light from a light source, wherein the light is transmitted in a first predetermined wavelength range by an illumination filter positioned between the light source and the ocular surface, and wherein the light in the first predetermined wavelength range excites a contrast agent bound to defects on the ocular surface; and (b) detecting a light signal emitted from the contrast agent, wherein the light signal is transmitted in a second predetermined wavelength range by an imaging filter to an image capture device, wherein the imaging filter is positioned between the ocular surface and the image capture device. In one aspect, the image capture device comprises an optical system with appropriate optics to increase depth of field in the image and transmits full field in focus image signals to a machine readable storage medium comprising instructions that provide quantitative analysis of contrast agent intensity and distribution.

The invention further provides methods of detecting an ocular surface disease, the method comprising: (a) illuminating the ocular surface of an eye of a patient with a light from a light source, wherein the light is polarized in a first orientation by an illumination filter positioned between the light source and the ocular surface, and wherein the light polarized in the first orientation excites a contrast agent bound to defects on the ocular surface; and (b) detecting a light signal emitted from the contrast agent, wherein the light signal is polarized in a second orientation by an imaging filter, and is transmitted by the imaging filter to an image capture device, wherein the imaging filter is positioned between the ocular surface and the image capture device. In one aspect, the image capture device comprises an optical system with appropriate optics to increase depth of field in the image and transmits full field in focus image signals to a machine readable storage medium comprising instructions that provide quantitative analysis of contrast agent intensity and distribution in an automated fashion such that there is little or no human intervention in obtaining contrast agent distribution data.

In certain aspects, the contrast agent can be a fluorescent dye, a colored dye, or a natural substance, such as blood.

In yet another aspect, the first filter and the second filter are polar filters, and are adjusted in opposite directions.

3

The invention also provides an ocular surface examination apparatus, comprising: (a) a light source; (b) an illumination means for directing light along an illumination path onto an ocular surface; (c) an imaging means for directing reflected light from the ocular surface of a patient along an imaging path to enable an image of the ocular surface to be viewed; (d) an illumination filter that transmits light in the illumination path; and (e) an imaging filter that transmits reflected light in the imaging path, wherein the light in the illumination path can pass through the first filter, but cannot pass through the second filter.

The invention also provides an ocular surface examination apparatus, comprising: (a) a light source for directing light along an illumination path onto an ocular surface; (b) an illumination filter that transmits light in the illumination path; (c) an imaging filter that transmits light reflected from a contrast agent on the ocular surface of a patient along an imaging path; and (d) an image capture device for detecting light reflected from the contrast agent on the ocular surface of the patient; wherein the light in the illumination path cannot pass through the imaging filter.

Specific preferred embodiments of the invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram showing a configuration of an ophthalmic apparatus of the invention, wherein light in the illumination path 2 is reflected toward the ocular surface of an eye 9 via a half-mirror 4.

FIG. 2 is a schematic diagram showing a configuration of an ophthalmic apparatus of the invention, wherein light in the illumination path 2 is directed toward the ocular surface of an eye 9 via a ring light 4.

FIG. 3A shows an image of an artificial cornea obtained in ambient room light.

FIG. 3B shows an image of an artificial cornea obtained with white excitation light and 532AF45 fluorescein emission filter.

FIG. 3C shows an image of artificial cornea obtained with white excitation light and an HQ480/40 excitation filter in the illumination path.

FIG. 4A shows an image of a cornea from a control, non-dry eye subject stained with 5  $\mu$ L of 2% sodium fluorescein for 3 minutes, followed by a saline wash.

FIG. 4B shows an image of a cornea from a dry eye subject stained with 5  $\mu$ L of 2% sodium fluorescein for 3 minutes, followed by a saline wash.

FIG. 5A shows an image of a cornea stained with fluorescein.

FIG. 5B shows an image of the fluorescein-stained cornea of FIG. 5A after image processing with a Fourier bandpass filter.

FIG. 6A shows an image of a corneal surface collected using spectral filtering to capture distribution of fluorescein staining.

FIG. 6B shows the image from FIG. 6A filtered with Fourier bandpass filters.

FIG. 6C shows threshold segmentation of the image from FIG. 6B.

FIG. 6D shows a measurement grid often referred the NEI (National Eye Institute) grid overlaid on to FIG. 6A. The NEI grid is most often used to manually score corneal staining by direct observation through a slit lamp of imaging device.

FIG. 7A shows an image of an ocular surface illuminated with left circularly polarized light.

4

FIG. 7B shows an image of an ocular surface illuminated with left circular polarized light and imaged through a right circular polar filter.

#### DETAILED DESCRIPTION

The invention relates to methods and apparatuses that can be used to quantitatively measure corneal staining. In particular, a method and apparatus of the invention can be used to capture images of a stained ocular surface (i.e. cornea) for the generation of objective information about ocular surface staining. The methods of the invention can be used, for example, as a diagnostic for ocular surface disease, such as dry eye, Sjogren's disease, infectious disease and contact lens wear problems, to measure therapeutic efficacy in clinical trials, or to measure efficacy of potential therapeutics in animal models of ocular surface diseases, such as dry eye. As used herein, the term "ocular surface disease" includes, but is not limited to, the aforementioned conditions as well as disorders such as infections, uveitis, conjunctivitis (including, for example, allergic conjunctivitis), keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface (including, for example, cicatrizing conjunctivitis, blepharitis, and scleritis), meibomianitis, conjunctival hyperemia, eyelid hyperemia, ocular rosacea, ocular inflammation (such as surgically-induced inflammation, inflammation caused by foreign bodies in the eye, any other type of wound to the ocular surface that causes inflammation), eye lid swelling, and the like.

An apparatus and methods of the invention can also be used, for example, to detect ocular side effects of drugs and/or drug candidates. For example, the methods can be used to detect hyperemia associated with administration of a drug or drug candidate given topically, locally, or systemically to a patient. A method and apparatus of the invention can also be used to monitor wound healing on the ocular surface.

In addition, an apparatus and methods of the invention can be used to identify the presence or absence of ocular surface defects in order to assess the health of a patient's eye.

Exemplary configurations of an apparatus of the invention are shown in FIG. 1 and FIG. 2, and are discussed in detail below.

In certain embodiments, a method and/or apparatus of the invention comprises illuminating an ocular surface with a light that is filtered at a predetermined wavelength or polar orientation. The light travels along an illumination path toward the ocular surface, which comprises a contrast agent that can be excited by the light beam emitted from a light source. The light signal emitted from the contrast agent travels along an imaging path toward an image capture device, such as a camera. Cameras can be of several types including digital single lens reflex cameras with RGB CMOS sensors or black and white CCD cameras. In a particular embodiment, the light signal captured by the image capture device is either spectrally isolated from the light in the illumination path, or has an opposite polar orientation relative to the light in the illumination path, as discussed in more detail below.

A suitable contrast agent that can be used in a method and/or apparatus of the invention is any agent that can bind to a defect on the ocular surface and be detected by specific light absorption and emission characteristics (i.e. color or fluorescence emission). For example, fluorescein, lissamine green, rose bengal have been used to measure surface irritation associated with dry eye (Bron et al, 2003, *Cornea* 22:640-650) and contact lens wear (Begley et al, 1994, *Int Contact Lens Clin* 21:7-13.). A contrast agent can be administered to a

5

patient via an eye drop, for example, aqueous solutions of sodium fluorescein or lissamine green are typically instilled as a one to five microliter drop onto the surface of the eye.

Alternatively, a contrast agent can be administered from a dye impregnated strip, such as sodium fluorescein impregnated strip (Fluorets™; Chauvin Pharmaceuticals, Essex, United Kingdom), in which a wetted strip is placed in contact with the eye at the lower lid margin for a period of a few minutes.

As used herein, a “patient” can be any mammal. Preferably, the patient is a human, monkey, rabbit, mouse, or rat. Most preferably, the patient is a human.

FIG. 1 provides a schematic diagram showing one configuration of an ophthalmic apparatus of the invention.

Referring to FIG. 1, a light source 1 emits light in an illumination path 2 toward a half-mirror 4. The light in the illumination path 2 passes through an illumination filter 3, then contacts the half-mirror 4, and is reflected toward the surface of an eye 9. The light in the illumination path 2 is adapted to excite a contrast agent present on the surface of the eye. A light signal emitted from the excited contrast agent travels in an imaging path 8 toward a lens 5. An imaging filter 7 is positioned in the imaging path 8 between the ocular surface of the eye 9 and the lens 5.

Images of corneal surface defects are captured by an image capture device 6 and transmitted to a machine readable storage medium 10. The machine readable storage medium 10 comprises instructions for providing quantitative analysis of contrast agent intensity and distribution. Images of corneal surface defects can be visualized via a display unit, such as a monitor, that is connected to the machine readable storage medium 10.

FIG. 2 shows a schematic diagram showing another configuration of an ophthalmic apparatus of the invention.

Referring to FIG. 2, a light source 1 emits light in an illumination path 2 toward an illumination device 4. The illumination device can be, for example, a fiber optic ring light. The light in the illumination path 2 passes through an illumination filter 3, then contacts the illumination device 4, which transmits the light toward the surface of an eye 9. The light in the illumination path 2 is adapted to excite a contrast agent present on the surface of the eye. Light emitted from the excited contrast agent travels in an imaging path 8 toward a lens 5. An imaging filter 7 is positioned in the imaging path 8 between the ocular surface of the eye 9 and the lens 5.

Images of corneal surface defects are captured by an image capture device 6 and transmitted to a machine readable storage medium 10. The machine readable storage medium 10 comprises instructions for providing quantitative analysis of contrast agent intensity and distribution. Images of corneal surface defects can be visualized via a display unit, such as a monitor, that is connected to the machine readable storage medium 10.

In certain embodiments, illumination of the ocular surface using a method and/or apparatus of the invention is accomplished with light having specific wavelength ranges and/or polarized light, and images of the ocular surface are captured at specific wavelength ranges and/or polarization to produce images that are free of specular images of the illumination system.

In one embodiment, the wavelength range of light used to illuminate the ocular surface is spectrally isolated from the light used to capture the images (i.e. the light in the illumination path 2 cannot pass through the filter 7 in the imaging path 8). Spectral isolation of the light in an illumination path 2 from that in the imaging path 8 can be accomplished, for example, using a set of bandpass filters, one filter for illumi-

6

nation and a different filter for image capture. The wavelength range of the two filters cannot overlap, and therefore have very large out-of-band optical densities. Consequently, no light from the light source 1 can pass into the image capture device 6 and be imaged. For example, where fluorescein is a contrast agent on the ocular surface of the eye 9, a method and/or apparatus of the invention can comprise an illumination filter 3 that can transmit light in a range of 465-500 nanometers, for optimum excitation of fluorescein, and an imaging filter 7 that can transmit light greater than 515 nanometers, for optimum detection of fluorescein. Depending on the spectral properties of the contrast agent, other wavelength ranges for absorption and detection would be preferred. The optical density for each filter outside of these ranges would be at least 5.0 (i.e., transmittance greater than or equal to 0.000001).

In another embodiment, a method and/or apparatus of the invention comprises polarized light to illuminate the ocular surface, wherein the illumination filter 3 and the imaging filter 7 are polar filters. For example, the ocular surface of an eye is illuminated with circularly polarized light, using an illumination filter 3 that is a left or right circular polar filter, and the imaging filter 7 is a right or left circular polar filter, respectively (i.e. where the illumination filter 3 is a left circular polar filter, the imaging filter 7 is a right circular polar filter). Alternatively, the ocular surface of an eye is illuminated with plane polarized light, wherein the illumination filter 3 and imaging filter 7 are adjusted in opposite directions.

The arrangement (i.e. the illumination filter and the imaging filter are in different light paths) and properties of the filters in an apparatus and/or method of the invention ensures that an accurate image of ocular surface defects is captured, wherein the image is free from illumination artifacts (e.g. specular or Purkinje images from the light source). For example, where the contrast agent is a fluorescent dye, the illumination filter can be selected to transmit light in a particular range of wavelengths capable of exciting the dye, while the imaging filter can be selected to transmit light at wavelengths that are outside the wavebands transmitted by the illumination filter. The imaging filter will transmit fluorescence from the dye while blocking fluorescence that is generated from other objects on the ocular surface. Thus, the only signal captured for analysis will be associated with defects on the ocular surface that are bound to the dye.

In certain embodiments, images of corneal surface defects are captured by an image capture device, where they are stored and/or transferred to a machine readable storage medium. The machine readable storage medium comprises a program of instructions stored thereon for causing an electrical processor to execute automated method steps for image analysis, which is performed using an adaptive threshold algorithm, in conjunction with the light filtering accomplished with the illumination filter and the imaging filter, to segment stained objects from digital images. The adaptive threshold method iteratively adjusts the segmentation threshold until the rate of change in the number of pixels in the segmented image has reached a predetermined level.

In other embodiments, an optical system can be used to increase depth of field in an image captured using a method or apparatus of the invention. For example, an “optical system” can be used to place an aperture in the optical imaging path that increases the depth of focus in the final image, or to adjust the focal plane of the imaging system such that several images collected at different focal planes are collected and electronically rendered into a single in-focus image of the ocular surface (e.g. extended depth of field rendering). In certain embodiments, the optical system can be incorporated into an

image capture device. An image that has been adjusted using the optical system is transmitted as a full field, in-focus image to a machine readable storage medium that comprises instructions that provide automated, quantitative analysis of contrast agent intensity and distribution. Automated analysis eliminates the possibility of human error in obtaining and/or interpreting the contrast agent distribution data.

The isolation or segmentation of stained objects in corneas stained with a contrast agent for size position and intensity measurements is not obvious, despite the fact the stained objects can be more quickly visualized in properly filtered, in-focus images. Faint background fluorescence of residual stain in the tear film and autofluorescence from the cornea and surrounding conjunctiva require the use of image processing to highlight the stained spots. Fourier image processing methods are one of several means to enhance the appearance and subsequent threshold segmentation of image objects. In certain embodiments, a method and/or apparatus of the invention can comprise the use of Fourier bandpass filtering to enhance and aid subsequent stained object detection.

Fourier image processing is based on the work of the French mathematician Jean Baptiste Joseph Fourier, which postulates that any measurement in time and space can be expressed as an equation of sin and cosine functions or, to use the Euler formula, a series of complex exponentials summed over an infinite range of frequencies. The Fourier transform is the mathematical operation that transforms the original measure or signal into an expression of complex exponentials with a range of amplitude coefficients and frequency terms. An image, being a two dimensional array of intensity measurements, can also be transformed to two dimensional arrays of complex exponentials. This Fourier transformation is often referred to as a transformation from the spatial domain to the frequency domain. In the frequency domain, one can highlight specific structures and remove others for subsequent analysis by removing certain frequencies from the transform and then calculating the inverse transform. For example, in stained cornea images, the bright conjunctiva surrounding the cornea and the diffuse background fluorescence are represented by lower frequency terms in the transform while stained spots are represented by high frequency terms. By multiplying the transform of the original image with a filter that reduces the low frequency terms and performing an inverse transform on the product, an image is created that has reduced the diffuse background and conjunctival intensities while maintaining the stained spots.

Thus, in certain embodiments of the invention, a Fourier band pass filter can be used with a predetermined frequency space to remove low frequency components (i.e., very large objects or background) and highlight high frequency components that include small punctate objects. Examples of potential filters include, but are not limited to, Gaussian and Butterworth filters. Fourier filtering advantageously permits detection of punctate stained regions against a varying background of unbound stain in the tear film (see Example 2 below, which illustrates process and results of Fourier band pass filter for detecting stained objects on the ocular surface).

All references cited in this application are expressly incorporated by reference herein for any purpose.

Unless otherwise required by context, singular terms used herein shall include pluralities and plural terms shall include the singular.

## EXAMPLES

The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as limiting the invention.

### Example 1

#### Spectral Filtering Removes Purkinje Images of the Illumination Source from Images of Specular Surfaces

The ability to spectrally remove the specular or Purkinje image from ocular surface fluorescence images was demonstrated with an artificial cornea prepared from a hard contact lens. For this a hard contact lens made of polymethylmethacrylate was coated with green fluorescent beads, (Bangs Laboratories, Inc, Fishers, Ind.) to simulate stained spots on a curve corneal surface. The spectral properties of these beads were similar to fluorescein. The artificial cornea was positioned in front of a Nikon digital single lens reflex camera and illuminated with a fiber optic ring light mounted to the lens of the camera. The fiber optic ring illuminator was configured such that band pass filters could be used to spectrally define the light emanating from the ring. Images were collected through either a green bandpass filter optimized for fluorescein emission wavelengths, (532+/-45 nm) or no filter.

The artificial cornea coated with fluorescent beads is shown in FIG. 3A illuminated with ambient white room light and imaged without a green blocking filter. A specular image of the dim room lamp was observed on the upper side of the lens surface. In FIG. 3B, the artificial cornea was illuminated with white light from a fiber optic ring light and an image was collected through the green bandpass filter. A bright specular image of the ring light was observed. In FIG. 3C, the artificial cornea was illuminated with filtered blue light, 480+/-40 nm; though the ring light and the images were collected with the green bandpass filter. The specular image of the ring was no longer observed and the fluorescent beads coating the surface became observable. The use of two filters, one for excitation and one for image collection, having non-overlapping wavelength ranges eliminated the specular image of the source illumination and allowed the beads to be more easily and consistently measured.

### Example 2

#### Spectral Filtering Removes Purkinje Images of the Illumination Source from Images of the Ocular Surface

A severe dry eye patient and a non-dry eye patient were subjected to corneal staining with 5  $\mu$ L of 2% sodium fluorescein for 3 minutes, followed by a saline wash (Unisol 4 Saline Solution, Alcon Laboratories, Inc., Fort Worth, Tex.). The stained eyes were imaged with a Haag-Streit BX-900 slit lamp. The Haag-Streit slit lamp consisted of a stereo biomicroscope, a combination flash lamp and modeling lamp for illuminating the eye and a Canon 40D digital camera and computer for image capture. The slit lamp was modified by the addition of a fluorescein excitation bandpass filter to the flash lamp output and the insertion of a fluorescein emission filter in the light path to the between the eye and the camera. The fluorescein excitation filter had a bandpass (transmission>90%) of 483+/-32 nm and the emission filter had a bandpass of 536+/-40 nm. The out-of-band optical densities

9

of these custom filters was designed to be  $\geq 6$ , hence no excitation light passed into the camera.

As shown in FIG. 4, corneal images from the control non-dry eye subject (A) revealed a relatively uniform cornea with no obvious stained lesions, while from the dry eye subject (B) exhibited with several brightly stained punctate spots. The spots represented defects or lesions in the corneal epithelial layer associated with the dry eye condition. These images were suitable for quantifying the position, size, intensity and shape of the stained lesions. Again there were no Purkinje images of the illuminating source in these images.

### Example 3

#### Fourier Analysis of Ocular Surface Defects of a Dry Eye Patient

The effect of the Fourier bandpass filtering process was illustrated in FIG. 5 and FIG. 6. The fluorescein corneal image in FIG. 5A was obtained with a camera based imaging system equipped with fluorescein spectral band pass filters as described above. The two dimensional Fourier transform of the image in FIG. 5A was then calculated using an unpadded fast Fourier transform algorithm found in most image analysis software. The transform was then multiplied by the Fourier transform of a low pass Gaussian filter and the inverse transform of the product was calculated to produce the image in FIG. 5B. As expected, the Fourier processing removed the low background brightness of the conjunctiva and background stain leading to an enhancement of the small speckled stained structures in the cornea (compare image in FIG. 5A and FIG. 5B).

The utility of the imaging method and the Fourier bandpass filtering process in measuring fluorescein stained objects in corneas is illustrated in FIG. 6A-D. As shown in FIG. 8A, the image collected using spectral filtering method captured the distribution of fluorescein staining on human cornea without Purkinje image of the lamp. The image in FIG. 6A was filtered using Fourier bandpass, to highlight fluorescein stained objects (FIG. 6B). Threshold segmentation of the image in FIG. 6B was performed, such that group pixels above a certain threshold intensity and size were isolated and overlaid in green. FIG. 6D shows detected objects illustrated in 6C along with a standard corneal scoring grid commonly referred to as the National Eye Institute (NEI) grid, recommended by the National Eye Institute for visually scoring staining use, (Lemp M.A. *Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes CLAO J.* 1995 October; 21(4):221-32). These results demonstrated that Fourier processing allowed one to enhance contrast in an image based on the size of object, and was independent of the objects mean intensity when compared to threshold based methods. The methods were ideally suited to the cornea images and for fluorescein stained corneal defects in particular.

### Example 4

#### Polar Filtering Eliminates Specular Images Reflecting from the Ocular Surface

The need to remove specular images of the illumination source from ocular surface images is not limited to fluorescein stained eyes. During the course of several other ocular examinations, such as measuring hyperemia or colored conjunctival stains, such as lissamine green or rose bengal, it would be advantageous to remove the specular images of the

10

source to facilitate subsequent analysis. For non-fluorescent imaging, polarization optics can be used to filter specular reflected light from ocular images. An example of this is shown in FIG. 7.

FIG. 7A shows an image of an ocular surface obtained by illuminating with left circularly polarized light using a ring light source and imaged without a polar filter in the eye to camera light path. The specular image of the ring light appeared as a bright white ring in the center of the eye (FIG. 7A). FIG. 7B, shows an image of the ocular surface illuminated with left circular polarized light using the same ring light source and imaged through a right circular polar filter in the eye to camera light path. The specular reflected light from the ring light was blocked by the cross polar filter and the image was free of specular artifact (FIG. 7B). Thus, polarized light filtering eliminated the Purkinje artifacts from the ocular surface image.

### Example 5

#### Measuring Changes in Conjunctival Hyperemia

Conjunctival hyperemia is a key symptom of allergic conjunctivitis and is an important endpoint in clinical efficacy and safety trials. Current methods for assessing hyperemia are highly subjective and inconsistent from site to site. The software and apparatus described herein were used to demonstrate objective and automatic quantification of conjunctival hyperemia, as follows.

The imaging system described herein, consisting of a modified slit lamp equipped with polarization optics described in Example 4 and a suite of software components was used to capture ocular surface images for automated image analysis of conjunctival blood vessel morphology. Software components included an image acquisition interface, a data synchronizer to upload images to a secure image-grading server, and an interface to review results and process images.

The system was successfully used to obtain and analyze conjunctival images from 12 patients with a history of allergic conjunctivitis following exposure to allergen. Result from automated image analysis were compared with results obtained by standard grading by trained clinicians who used a standardized 9-point redness scale from 0 (none) to 4 (extremely severe) in 0.5-unit increments. While the grading analyses provided grading scores, automated measurements provided an array of objective microanatomical data about conjunctival vasculature that were not evident to a clinical observer. This data included vessel area, vessel diameter, total vessel length, vessel density (vessel area/total area), and other shape factors. Automated image analysis results provided an objective measure of several vascular changes associated with allergen-induced hyperemia, some of which were not evident by manual grading. Compared with manual grading of conjunctival hyperemia, these tools were found to be faster, more reliable, more accurate, and less prone to human bias.

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

What is claimed is:

1. A method of detecting an ocular surface disease, the method comprising:  
illuminating the cornea of an ocular surface of an eye of a patient with a light from a light source, wherein the light is transmitted in a first predetermined wavelength range

11

by an illumination filter positioned between the light source and the ocular surface, and wherein the light in the first predetermined wavelength range excites a contrast agent bound to defects on the ocular surface;

capturing, with a camera, a light signal emitted from the contrast agent to generate a full-field, in focus image of the cornea having a depth of field sufficient to capture a full depth of the cornea, wherein the light signal is transmitted in a second predetermined wavelength range by an imaging filter to the camera, wherein the imaging filter comprises a Fourier bandpass filter removing low frequency components and enhancing detection of the contrast agent;

wherein the camera transmits signals representing the full-field, in focus image of the cornea for image analysis by a processor in communication with a machine readable storage medium comprising instructions that, when executed by the processor, provide quantitative analysis of contrast agent intensity and distribution, and wherein the ocular surface disease is uveitis, conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, meibomianitis, conjunctival hyperemia, eyelid hyperemia, ocular rosacea, ocular inflammation, or eye lid swelling; and segmenting stained objects within the full-field, in focus image to create a segmented image using a segmentation threshold.

2. The method of claim 1, wherein the optical density of the illumination filter at wavelengths other than the first predetermined wavelength range is at least 5.0 and the optical density of the imaging filter is at least 5.0 at wavelengths other than the second predetermined wavelength range.

3. The method of claim 1, wherein the contrast agent is fluorescein, the illumination filter transmits light having a wavelength in a range of 465 to 500 nm, and the imaging filter filters light to block all light that does not have a wavelength greater than 515 nm to avoid overlapping wavelengths.

4. A method of detecting an ocular surface disease, the method comprising:

illuminating the cornea of an ocular surface of an eye of a patient with a light from a light source, wherein the light is polarized in a first orientation by an illumination filter positioned between the light source and the ocular surface, and wherein the light polarized in the first orientation excites a contrast agent bound to defects on the ocular surface;

capturing, with a camera, a light signal emitted from the contrast agent to generate a full-field, in focus image of the cornea having a depth of field sufficient to capture a full depth of the cornea, wherein the light signal is polarized in a second orientation by an imaging filter, and is transmitted by the imaging filter to the camera, and wherein a Fourier bandpass filter is applied to the full-field, in focus image removing low frequency components and enhancing detection of the contrast agent;

wherein the camera transmits signals representing the full-field, in focus image of the cornea for image analysis by a processor in communication with a machine readable storage medium comprising instructions that, when executed by the processor, provide quantitative analysis of contrast agent intensity and distribution, and wherein the ocular surface disease is uveitis, conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, meibomianitis,

12

conjunctival hyperemia, eyelid hyperemia, ocular rosacea, ocular inflammation, or eye lid swelling;

segmenting stained objects within the full-field, in focus image to create a segmented image using a segmentation threshold; and

iteratively adjusting the segmentation threshold until a rate of change in a number of pixels in the segmented full-field, in focus image has reached a predetermined level.

5. The method of claim 4, wherein the illumination filter and the imaging filter are polar filters, and are adjusted in opposite directions.

6. The method of claim 4, wherein the illumination filter and the imaging filter are circular polar filters, and wherein one of the filters is left circular and the other is right circular.

7. The method of claim 1, wherein the illumination filter and the imaging filter are polar filters, and are adjusted in opposite directions.

8. The method of claim 4, wherein the illumination filter transmits light having a wavelength in a range of 465 to 500 nm, and the imaging filter filters light to block all light that does not have a wavelength greater than 515 nm to avoid overlapping wavelengths.

9. The method of claim 1, further comprising:

capturing a plurality of images of the cornea with the camera, each of the plurality of images being captured at a different focal plane; and

rendering the plurality of images into the full-field, in focus image of the cornea.

10. The method of claim 1, further comprising iteratively adjusting the segmentation threshold until a rate of change in a number of pixels in the segmented full-field, in focus image has reached a predetermined level.

11. A method of detecting an ocular surface disease, the method comprising:

illuminating the cornea of an ocular surface of an eye of a patient with a light from a light source, wherein the light is transmitted in a first wavelength range by an illumination filter positioned between the light source and the ocular surface, and wherein the light in the first wavelength range excites a contrast agent bound to defects on the ocular surface;

capturing, with a camera, a light signal emitted from the contrast agent to generate a full-field, in focus image of the cornea having a depth of field sufficient to capture a full depth of the cornea, wherein the light signal is transmitted in a second wavelength range by an imaging filter to the camera, wherein the imaging filter is positioned between the ocular surface and the camera;

wherein the camera transmits signals representing the full-field, in focus image of a cornea for image analysis by a processor in communication with a machine readable storage medium comprising instructions that, when executed by the processor, provide quantitative analysis of contrast agent intensity and distribution and wherein the illumination filter and the imaging filter are polar filters that are adjusted in opposite directions; and segmenting stained objects from the full-field, in focus image to create a segmented image using an adaptive segmentation threshold.

12. The method of claim 11, wherein the illumination filter transmits light having a wavelength in a range of 465 to 500 nm, and the imaging filter filters light to block all light that does not have a wavelength greater than 515 nm to avoid overlapping wavelengths.

13. The method of claim 11, comprising transmitting signals from the camera to a machine readable storage medium, the signals comprising instructions that provide quantitative

**13**

analysis of contrast agent intensity and distribution for detecting the ocular surface disease of at least one of conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), or atopic keratoconjunctivitis (AKC).

**14.** The method of claim **11**, wherein the depth of focus is about 2.8 millimeters.

\* \* \* \* \*

**14**